. 2020 Dec 1;34(23-24):1577–1598. doi: 10.1101/gad.343251.120
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.
Table 1.
FDA approved targeted therapies for solid tumors
